Qui Tam case against NeoGenomics dismissed with prejudice

NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM) announced today that it has been notified that the Qui Tam complaint filed against it and several other healthcare companies in 2009 has been voluntarily dismissed with prejudice by the relator in the case.  As a result, no further action will be taken against NeoGenomics in this matter.

Douglas VanOort, the Company's Chairman and CEO, stated, "We are pleased, but not surprised that this case has been dismissed.  NeoGenomics constantly strives to operate with impeccable integrity and at the highest standards of conduct in our industry.  After a year of review by the U.S. Attorney's office, this case was dismissed with prejudice.  Frivolous lawsuits like this are costly to government and businesses, and divert management attention from growth, job creation, and improving our health care system.  Reform is needed to eliminate incentives to file lawsuits with unfounded complaints in pursuit of 'Jackpot Justice'.   The plaintiff in this case should be ashamed of his actions and should be made to publicly apologize to the defendants and reimburse them for the legal expenses."